<DOC>
	<DOC>NCT00321997</DOC>
	<brief_summary>The purpose of this study is to compare the ability of different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or impriving vision in patients with wet AMD when compared to placebo injections.</brief_summary>
	<brief_title>A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Subjects of either gender, aged 50 years or greater. Subfoveal choroidal neovascularization (CNV) due to AMD. Best corrected visual acuity in the study eye between 20/40 and 20/320. Any prior subfoveal thermal laser therapy.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>AMD</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Macugen</keyword>
	<keyword>pegaptanib sodium</keyword>
</DOC>